304 related articles for article (PubMed ID: 33057100)
1. Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease.
Gonzalez-Hunt CP; Thacker EA; Toste CM; Boularand S; Deprets S; Dubois L; Sanders LH
Sci Rep; 2020 Oct; 10(1):17293. PubMed ID: 33057100
[TBL] [Abstract][Full Text] [Related]
2. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.
Howlett EH; Jensen N; Belmonte F; Zafar F; Hu X; Kluss J; Schüle B; Kaufman BA; Greenamyre JT; Sanders LH
Hum Mol Genet; 2017 Nov; 26(22):4340-4351. PubMed ID: 28973664
[TBL] [Abstract][Full Text] [Related]
3. R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils.
Fan Y; Nirujogi RS; Garrido A; Ruiz-Martínez J; Bergareche-Yarza A; Mondragón-Rezola E; Vinagre-Aragón A; Croitoru I; Gorostidi Pagola A; Paternain Markinez L; Alcalay R; Hickman RA; Düring J; Gomes S; Pratuseviciute N; Padmanabhan S; Valldeoriola F; Pérez Sisqués L; Malagelada C; Ximelis T; Molina Porcel L; Martí MJ; Tolosa E; Alessi DR; Sammler EM
Acta Neuropathol; 2021 Sep; 142(3):475-494. PubMed ID: 34125248
[TBL] [Abstract][Full Text] [Related]
4. Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils.
Fan Y; Howden AJM; Sarhan AR; Lis P; Ito G; Martinez TN; Brockmann K; Gasser T; Alessi DR; Sammler EM
Biochem J; 2018 Jan; 475(1):23-44. PubMed ID: 29127255
[TBL] [Abstract][Full Text] [Related]
5. A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls.
Vissers MFJM; Troyer MD; Thijssen E; Pereira DR; Heuberger JAAC; Groeneveld GJ; Huntwork-Rodriguez S
Clin Transl Sci; 2023 Aug; 16(8):1408-1420. PubMed ID: 37177855
[TBL] [Abstract][Full Text] [Related]
6. LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients.
Atashrazm F; Hammond D; Perera G; Bolliger MF; Matar E; Halliday GM; Schüle B; Lewis SJG; Nichols RJ; Dzamko N
Mov Disord; 2019 Mar; 34(3):406-415. PubMed ID: 30597610
[TBL] [Abstract][Full Text] [Related]
7. Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor.
Bright JM; Carlisle HJ; Toda AMA; Murphy M; Molitor TP; Wren P; Andruska KM; Liu E; Barlow C
Mov Disord; 2021 Jun; 36(6):1362-1371. PubMed ID: 33836114
[TBL] [Abstract][Full Text] [Related]
8. Accurate MS-based Rab10 Phosphorylation Stoichiometry Determination as Readout for LRRK2 Activity in Parkinson's Disease.
Karayel Ö; Tonelli F; Virreira Winter S; Geyer PE; Fan Y; Sammler EM; Alessi DR; Steger M; Mann M
Mol Cell Proteomics; 2020 Sep; 19(9):1546-1560. PubMed ID: 32601174
[TBL] [Abstract][Full Text] [Related]
9. Preclinical modeling of chronic inhibition of the Parkinson's disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo.
Kluss JH; Mazza MC; Li Y; Manzoni C; Lewis PA; Cookson MR; Mamais A
Mol Neurodegener; 2021 Mar; 16(1):17. PubMed ID: 33741046
[TBL] [Abstract][Full Text] [Related]
10. Centrosomal cohesion deficits as cellular biomarker in lymphoblastoid cell lines from LRRK2 Parkinson's disease patients.
Fernández B; Lara Ordóñez AJ; Fdez E; Mutez E; Comptdaer T; Leghay C; Kreisler A; Simonin C; Vandewynckel L; Defebvre L; Destée A; Bleuse S; Taymans JM; Chartier-Harlin MC; Hilfiker S
Biochem J; 2019 Oct; 476(19):2797-2813. PubMed ID: 31527116
[TBL] [Abstract][Full Text] [Related]
11. Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker.
Perera G; Ranola M; Rowe DB; Halliday GM; Dzamko N
Sci Rep; 2016 Aug; 6():31391. PubMed ID: 27503089
[TBL] [Abstract][Full Text] [Related]
12.
Wauters F; Cornelissen T; Imberechts D; Martin S; Koentjoro B; Sue C; Vangheluwe P; Vandenberghe W
Autophagy; 2020 Feb; 16(2):203-222. PubMed ID: 30945962
[TBL] [Abstract][Full Text] [Related]
13. LRRK2 impairs PINK1/Parkin-dependent mitophagy via its kinase activity: pathologic insights into Parkinson's disease.
Bonello F; Hassoun SM; Mouton-Liger F; Shin YS; Muscat A; Tesson C; Lesage S; Beart PM; Brice A; Krupp J; Corvol JC; Corti O
Hum Mol Genet; 2019 May; 28(10):1645-1660. PubMed ID: 30629163
[TBL] [Abstract][Full Text] [Related]
14. LRRK2 Phosphorylation: Behind the Scenes.
De Wit T; Baekelandt V; Lobbestael E
Neuroscientist; 2018 Oct; 24(5):486-500. PubMed ID: 29385885
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation.
Su YC; Qi X
Hum Mol Genet; 2013 Nov; 22(22):4545-61. PubMed ID: 23813973
[TBL] [Abstract][Full Text] [Related]
16. Kinase activity of mutant LRRK2 manifests differently in hetero-dimeric vs. homo-dimeric complexes.
Leandrou E; Markidi E; Memou A; Melachroinou K; Greggio E; Rideout HJ
Biochem J; 2019 Feb; 476(3):559-579. PubMed ID: 30670570
[TBL] [Abstract][Full Text] [Related]
17. G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage.
Pena N; Richbourg T; Gonzalez-Hunt CP; Qi R; Wren P; Barlow C; Shanks NF; Carlisle HJ; Sanders LH
NPJ Parkinsons Dis; 2024 Mar; 10(1):49. PubMed ID: 38429321
[TBL] [Abstract][Full Text] [Related]
18. Accumulation of mitochondrial 7S DNA in idiopathic and LRRK2 associated Parkinson's disease.
Podlesniy P; Puigròs M; Serra N; Fernández-Santiago R; Ezquerra M; Tolosa E; Trullas R
EBioMedicine; 2019 Oct; 48():554-567. PubMed ID: 31631040
[TBL] [Abstract][Full Text] [Related]
19. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
[TBL] [Abstract][Full Text] [Related]
20. An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 Cohorts.
Padmanabhan S; Lanz TA; Gorman D; Wolfe M; Joyce A; Cabrera C; Lawrence-Henderson R; Levers N; Joshi N; Ma TC; Liong C; Narayan S; Alcalay RN; Hutten SJ; Baptista MAS; Merchant K
J Parkinsons Dis; 2020; 10(2):623-629. PubMed ID: 32007961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
